Drugs / RN3161
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07245771 | Nov 2025 → Feb 2027 expected | obesity disorder | Ikaria Bioscience Pty Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-12-15 | Shanghai Rona Therapeutics Co., Ltd. | Results Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development ronatherapeutics.com ↗
Cohort 1 was completed successfully with a favorable initial safety and tolerability profile, marking the first clinical milestone for Rona’s INHBE program. |
| 2025-09-15 | Shanghai Rona Therapeutics Co., Ltd. | Regulatory Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity ronatherapeutics.com ↗
Rona Therapeutics , a global leader in developing next-generation RNAi therapeutics, announced today the successful submission of RN3161 to the Australian Human Research Ethics Committee (HREC). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-15 | Shanghai Rona Therapeutics Co., Ltd. | Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development ronatherapeutics.com ↗ |
| 2025-09-15 | Shanghai Rona Therapeutics Co., Ltd. | Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity ronatherapeutics.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RN3161 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07245771 ↗ |